CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM120802
035-os BibID:(Scopus)85191357998 (WoS)001205799400001
Első szerző:Ameri, Pietro
Cím:A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function / Pietro Ameri, Valentina Mercurio, Piero Pollesello, Markus S. Anker, Johannes Backs, Antoni Bayes-Genis, Barry A. Borlaug, Daniel Burkhoff, Sergio Caravita, Stephen Y. Chan, Frances de Man, George Giannakoulas, Aránzazu González, Marco Guazzi, Paul M. Hassoun, Anna R. Hemnes, Christoph Maack, Brendan Madden, Vojtech Melenovsky, Oliver J. Müller, Zoltan Papp, Soni Savai Pullamsetti, Peter P. Rainer, Margaret M. Redfield, Stuart Rich, Gabriele G. Schiattarella, Hall Skaara, Kostantinos Stellos, Ryan J. Tedford, Thomas Thum, Jean Luc Vachiery, Peter van der Meer, Sophie Van Linthout, Piotr Pruszczyk, Petar Seferovic, Andrew J. S. Coats, Marco Metra, Giuseppe Rosano, Stephan Rosenkranz, Carlo Gabriele Tocchetti
Dátum:2024
ISSN:1388-9842 1879-0844
Megjegyzések:Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Drug
Heart failure
Pulmonary hypertension
Therapy
Translational
Megjelenés:European Journal Of Heart Failure. - 26 : 4 (2024), p. 707-729. -
További szerzők:Mercurio, Valentina Pollesello, Piero Anker, Markus S. Backs, Johannes Bayes-Genis, Antoni Borlaug, Barry A. Burkhoff, Daniel Caravita, Sergio Chan, Stephen Man, Frances de Giannakoulas, George González, Aránzazu Guazzi, Marco Hassoun, Paul M. Hemnes, Anna R. Maack, Christoph Madden, Brendan Melenovsky, Vojtech Müller, Oliver J. Papp Zoltán (1965-) (kardiológus, élettanász) Pullamsetti, Soni Savai Rainer, Peter P. Redfield, Margaret M. Rich, Stuart Schiattarella, Gabriele G. Skaara, Hall Stellos, Kostantinos Tedford, Ryan J. Thum, Thomas Vachiery, Jean Luc Meer, Peter van der Linthout, Sophie Van Pruszczyk, Piotr Seferović, Petar M. Coats, Andrew Metra, Marco Rosano, Giuseppe M. C. Rosenkranz, Stephan Tocchetti, Carlo Gabriele
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM121795
035-os BibID:(WoS)001233134300001 (Scopus)85194551593
Első szerző:Beghini, Alberto
Cím:2024 update in heart failure / Alberto Beghini, Antonio Maria Sammartino, Zoltán Papp, Stephan von Haehling, Jan Biegus, Piotr Ponikowski, Marianna Adamo, Luigi Falco, Carlo Mario Lombardi, Matteo Pagnesi, Gianluigi Savarese, Marco Metra, Daniela Tomasoni
Dátum:2025
ISSN:2055-5822
Megjegyzések:In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of the 2021 HF guidelines introduced new key recommendations based on the results of the last years of science. First, two drugs, sodium glucose co-transporter-2 (SGLT2) inhibitors and finerenone, a novel nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), are recommended for the prevention of HF in patients with diabetic chronic kidney disease (CKD). Second, SGLT2 inhibitors are now recommended for the treatment of HF across the entire left ventricular ejection fraction spectrum. The benefits of quadruple therapy in patients with HF with reduced ejection fraction (HFrEF) are well established. Its rapid and early up-titration along with a close follow-up with frequent clinical and laboratory re-assessment after an episode of acute HF (the so-called ♭high-intensity care' strategy) was associated with better outcomes in the STRONG-HF trial. Patients experiencing an episode of worsening HF might require a fifth drug, vericiguat. In the STEP-HFpEF-DM and STEP-HFpEF trials, semaglutide 2.4 mg once weekly administered for 1 year decreased body weight and significantly improved quality of life and the 6 min walk distance in obese patients with HF with preserved ejection fraction (HFpEF) with or without a history of diabetes. Further data on safety and efficacy, including also hard endpoints, are needed to support the addition of acetazolamide or hydrochlorothiazide to a standard diuretic regimen in patients hospitalized due to acute HF. In the meantime, PUSH-AHF supported the use of natriuresis-guided diuretic therapy. Further options and most recent evidence for the treatment of HF, including specific drugs for cardiomyopathies (i.e., mavacamten in hypertrophic cardiomyopathy and tafamidis in transthyretin cardiac amyloidosis), device therapies, cardiac contractility modulation and percutaneous treatment of valvulopathies, with the recent finding from the TRILUMINATE Pivotal trial, are also reviewed in this article.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SGLT2 inhibitors
comorbidities
finerenone
heart failure
prevention
prognosis
treatment
Megjelenés:ESC heart failure. - 12 : 1 (2025), p. 8-42. -
További szerzők:Sammartino, Antonio Maria Papp Zoltán (1965-) (kardiológus, élettanász) Haehling, Stephan von Biegus, Jan Ponikowski, Piotr Adamo, Marianna Falco, Luigi Lombardi, Carlo Mario Pagnesi, Matteo Savarese, Gianluigi Metra, Marco Tomasoni, Daniela
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM069431
Első szerző:Farmakis, Dimitrios
Cím:Levosimendan beyond inotropy and acute heart failure : evidence of pleiotropic effects on the heart and other organs : an expert panel position paper / Farmakis Dimitrios, Alvarez Julian, Gal Tuvia Ben, Brito Dulce, Fedele Francesco, Fonseca Candida, Gordon Anthony C., Gotsman Israel, Grossini Elena, Guarracino Fabio, Harjola Veli-Pekka, Hellman Yaron, Heunks Leo, Ivancan Visnja, Karavidas Apostolos, Kivikko Matti, Lomivorotov Vladimir, Longrois Dan, Masip Josep, Metra Marco, Morelli Andrea, Nikolaou Maria, Papp Zoltán, Parkhomenko Alexander, Poelzl Gerhard, Pollesello Piero, Ravn Hanne Berg, Rex Steffen, Riha Hynek, Ricksten Sven-Erik, Schwinger Robert H. G., Vrtovec Bojan, Yilmaz M. Birhan, Zielinska Marzenna, Parissis John
Dátum:2016
ISSN:0167-5273
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:International Journal Of Cardiology 222 (2016), p. 303-312. -
További szerzők:Alvarez, Julian Gal, Tuvia Ben Brito, Dulce Fedele, Francesco Fonseca, Candida Gordon, Anthony C. Gotsman, Israel Grossini, Elena Guarracino, Fabio Harjola, Veli-Pekka Hellman, Yaron Heunks, Leo Ivancan, Visnja Karavidas, Apostolos Kivikko, Matti Lomivorotov, Vladimir Longrois, Dan Masip, Josep Metra, Marco Morelli, Andrea Nikolaou, Maria Papp Zoltán (1965-) (kardiológus, élettanász) Parkhomenko, Alexander Poelzl, Gerhard Pollesello, Piero Ravn, Hanne Berg Rex, Steffen Riha, Hynek Ricksten, Sven-Erik Schwinger, Robert H. G. Vrtovec, Bojan Yilmaz, Mehmet Birhan Zielinska, Marzenna Parissis, John
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM076736
035-os BibID:(WoS)000501730100012 (Scopus)85075326564
Első szerző:Maack, Christoph
Cím:Treatments targeting inotropy : a position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology / Christoph Maack, Thomas Eschenhagen, Nazha Hamdani, Frank R. Heinzel, Alexander R. Lyon, Dietmar J. Manstein, Joseph Metzger, Zoltán Papp, Carlo G. Tocchetti, M. Birhan Yilmaz, Stefan D. Anker, Jean-Luc Balligand, Johann Bauersachs, Dirk Brutsaert, Lucie Carrier, Stefan Chlopicki, John G. Cleland, Rudolf A. de Boer, Alexander Dietl, Rodolphe Fischmeister, Veli-Pekka Harjola, Stephane Heymans, Denise Hilfiker-Kleiner, Johannes Holzmeister, Gilles de Keulenaer, Giuseppe Limongelli, Wolfgang A. Linke, Lars H. Lund, Josep Masip, Marco Metra, Christian Mueller, Burkert Pieske, Piotr Ponikowski, Arsen Ristic, Frank Ruschitzka, Petar M. Seferovic, Hadi Skouri, Wolfram H. Zimmermann, Alexandre Mebazaa
Dátum:2019
ISSN:0195-668X
Megjegyzések:Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2+. Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation-contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.
Tárgyszavak:idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Heart failure
Acute decompensated heart failure
Inotropes
Cardiogenic shock
Excitation-contraction coupling
Calcium
Sarcomeres
Mitochondria
Energetics
Adrenergic receptors
Contractility
Levosimendan
Omecamtiv mecarbil
Nitroxyl
Megjelenés:European Heart Journal. - 40 : 44 (2019), p. 3626-3640. -
További szerzők:Eschenhagen, Thomas Hamdani, Nazha Heinzel, Frank R. Lyon, Alexander Manstein, Dietmar J. Metzger József Papp Zoltán (1965-) (kardiológus, élettanász) Tocchetti, Carlo Gabriele Yilmaz, Mehmet Birhan Anker, Stefan D. Balligand, Jean-Luc Bauersachs, Johann Brutsaert, Dirk L. Carrier, Lucie Chlopicki, Stefan Cleland, John G. Boer, Rudolf A. de Dietl, Alexander Fischmeister, Rodolphe Harjola, Veli-Pekka Heymans, Stephane Hilfiker-Kleiner, Denise Holzmeister, Johannes De Keulenaer, Gilles Limongelli, Giuseppe Linke, Wolfgang A. Lund, Lars H. Masip, Josep Metra, Marco Mueller, Christian Pieske, Burkert Ponikowski, Piotr Ristić, Arsen D. Ruschitzka, Frank Seferović, Petar M. Skouri, Hadi Zimmermann, Wolfram H. Mebazaa, Alexandre
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM125677
035-os BibID:(scopus)85196289402 (wos)001250584500001
Első szerző:Seferović, Petar M.
Cím:Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases / Seferovic Petar M., Paulus Walter J., Rosano Giuseppe, Polovina Marija, Petrie Mark C., Jhund Pardeep S., Tschöpe Carsten, Sattar Naveed, Piepoli Massimo, Papp Zoltán, Standl Eberhard, Mamas Mamas A., Valensi Paul, Linhart Ales, Lalic Nebojsa, Ceriello Antonio, Döhner Wolfram, Ristic, Arsen, Milinkovic Ivan, Seferovic Jelena, Cosentino Francesco, Metra Marco, Coats Andrew J. S.
Dátum:2024
ISSN:1388-9842 1879-0844
Megjegyzések:The association between type 2 diabetes mellitus (T2DM) and heart failure (HF) has been firmly established; however, the entity of diabetic myocardial disorder (previously called diabetic cardiomyopathy) remains a matter of debate. Diabetic myocardial disorder was originally described as the occurrence of myocardial structural/functional abnormalities associated with T2DM in the absence of coronary heart disease, hypertension and/or obesity. However, supporting evidence has been derived from experimental and small clinical studies. Only a minority of T2DM patients are recognized as having this condition in the absence of contributing factors, thereby limiting its clinical utility. Therefore, this concept is increasingly being viewed along the evolving HF trajectory, where patients with T2DM and asymptomatic structural/functional cardiac abnormalities could be considered as having pre-HF. The importance of recognizing this stage has gained interest due to the potential for current treatments to halt or delay the progression to overt HF in some patients. This document is an expert consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. It summarizes contemporary understanding of the association between T2DM and HF and discuses current knowledge and uncertainties about diabetic myocardial disorder that deserve future research. It also proposes a new definition, whereby diabetic myocardial disorder is defined as systolic and/or diastolic myocardial dysfunction in the presence of diabetes. Diabetes is rarely exclusively responsible for myocardial dysfunction, but usually acts in association with obesity, arterial hypertension, chronic kidney disease and/or coronary artery disease, causing additive myocardial impairment.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Diabetic myocardial disorder
Type 2 diabetes mellitus
Heart failure
Cardiac abnormalities
Risk assessment
Prevention
Treatment
Megjelenés:European Journal Of Heart Failure. - 26 (2024), p. 1893-1903. -
További szerzők:Paulus, Walter J. Rosano, Giuseppe M. C. Polovina, Marija Petrie, Mark C. Jhund, Pardeep S. Tschöpe, Carsten Sattar, Naveed Piepoli, Massimo Papp Zoltán (1965-) (kardiológus, élettanász) Standl, Eberhard Mamas, Mamas A. Valensi, Paul Linhart, Ales Lalić, Nebojša Ceriello, Antonio Döhner, Wolfram Ristić, Arsen D. Milinković, Ivan Seferović, Jelena Cosentino, Francesco Metra, Marco Coats, Andrew
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.